Tryptamine Therapeutics (AU:TYP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tryptamine Therapeutics has successfully completed its Phase 1b trial of TRP-8803, an IV-infused psilocin formulation, in obese subjects, demonstrating safety and scalability. The rapid trial completion underscores the drug’s potential for further research, with Phase 2 trial planning already underway to explore its efficacy in weight-related conditions such as Binge Eating Disorder. This advancement positions TRP-8803 as a promising candidate in the neuroplastic pharmaceuticals market, offering faster onset and precise control compared to oral psilocybin.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ZMI, TBAL: 2 Canadian Balanced ETFs to Shield Your Returns
- Class Action Lawsuit Against Paragon 28, Inc. (NYSE:FNA)
- 3 Penny Stocks to Watch Now, 11/29/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
